People with type 2 diabetes may have an increased risk of developing Parkinson’s disease and for experiencing faster Parkinson’s progression, according to a large-scale analysis of past research. The study, “Type 2 Diabetes as a Determinant of Parkinson’s Disease Risk and Progression,” was published in the…
ANVS401, an investigational therapy for neurodegenerative diseases being developed by Annovis Bio, improved the speed and coordination of people with Parkinson’s disease in a Phase 2a clinical trial, an interim analysis suggests. “The results from this interim analysis are very encouraging. This brings us one step closer to…
Newron Pharmaceuticals and Zambon Pharma agreed to jointly support a potentially pivotal clinical trial of Xadago (safinamide) as a treatment of levodopa-induced dyskinesia in people with Parkinson’s disease. Under the terms of the agreement, Newron and Zambon will evenly share the cost of the intended study. Newron, which developed…
Researchers at the Sheffield Institute for Translational Neuroscience (SITraN) have been awarded £1.2 million ($1.67 million) from Parkinson’s UK to develop new treatments that slow progression of the disease. “This new funding will greatly accelerate the project and shows our commitment to working with ground-breaking academic researchers in the UK…
People with Parkinson’s disease have substantial changes in the bacteria living in their gut relative to people without this neurodegenerative disorder, an analysis underscores. “This dysbiosis [microbial imbalance] might result in a pro-inflammatory status which could be linked to the recurrent gastrointestinal symptoms affecting PD [Parkinson’s disease] patients,” its…
Three Canadian research centers and one drug discovery firm are collaborating to design new medicines to treat levodopa-induced dyskinesia in Parkinson’s disease, according to a press release. Nearly all people with Parkinson’s receive levodopa to treat the movement difficulties caused by the body’s loss of its own…
Centogene has completed enrollment of 10,000 participants in its two-year global study assessing the contribution of genetic factors in the development of Parkinson’s disease. “We are pleased to have reached such a pivotal point in our Parkinson’s disease study,” Peter Bauer, MD, chief genomic officer at Centogene, said…
People diagnosed with rheumatoid arthritis (RA) are at a significantly lower risk of developing Parkinson’s disease (PD) five or more years later, according to a large Swedish population study. This lesser risk — a drop of at least 35% — is possibly due to the anti-inflammatory…
Abbott has launched its NeuroSphere Virtual Clinic, a U.S. Food and Drug Administration (FDA)-approved digital technology that allows remote patient-doctor communication, increasing medical care access for patients with Parkinson’s disease and other movement disorders. “NeuroSphere Virtual Clinic solves considerable issues patients with movement disorders, such as Parkinson’s disease…
An investigative disease-modifying treatment by Yumanity Therapeutics, called YTX-7739, was found to improve motor skills and lessen toxic protein clumping in a mouse model of Parkinson’s disease (PD), the company reported in a press release. Data…
Get regular updates to your inbox.
